[1] Arnett FC, Edworthy SM, Block DA, et al. The 1987 revised ARA criteria for rheumatoid arthritis (RA)[J]. Arthritis Rheum, 1987, 30(Suppl 17):45-6.
[2] 陈妙兰主编.中国恶性常见肿瘤诊治规范[M].第9分册.北京:人民卫生出版社,1992.4.
[3] Naschitz JE, Yeshurun D, Rosner 1. Rheumatic manifestations of occult cancer[J]. Cancer, 1995,75: 2954-8.
[4] 施守义,乔向阳.多发性肌炎和皮肌炎[A].见:蒋明,朱立平,林孝义.风湿病学[M].北京:科学出版社,1995.1083-91.
[5] Chen YJ, Wu CY, Shen JL. Predicting fators of malignancy in dermatomyositis and polymyositis: a case-control study[J]. Br J Dermatol, 2001, 144: 825-31.
[6] Mebazaa A, Boussen H, Nouiva R, et al. Dermatomysitis and malignancy in Tunisia: a multicenter national restrospective study of 20cases[J]. J Am Acad Dermatol, 2003, 48: 530-4.
[7] Vardy J, Wong E, Izard M, et al. Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngnal cancer in a patient with dermatomyositis: a case report with literature review[J]. Anticaner Drugs, 2002, 13: 327-30.
[8] Korolopoulou P, Oates J, Kittas C, et al. p53 c-myc, p62 and proliferation cell nulear antigen (PCNA) expression in non-Hodgkin’s lymphomas[J]. J Clin Pathol, 1994, 47: 9-14.
[9] Blomadal L, Lofstrom B, Yin L, et al. An increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus[J]. Scand J Rheumatol, 2002, 31 (2): 66-71.
[10] 蒋明,朱立平,林孝义.风湿病学[M].北京:科学出版社,1995.1750-7.
[11] Ellot RW, Essenhigh DM, Moreley AR. Cyclophosphamide.treatment of systemic lupus erythematosus[J]. Curr Opin Rheumatol,1993, 5(5): 570-4. |
